Back to discover
Disease

Multiple Sclerosis

Late-stage therapeutic developmentActively researchedRising momentum
62
Publications
24
Clinical trials
12
Related conditions
2
Related treatments
5
Related proteins
2025
Latest publication
Current focus
Therapeutic developmentInflammation & immunityMetabolic & lifestyle factorsDisease mechanisms & pathology
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Neuroinflammation across neurological diseases.

Research2025-06-19Science (New York, N.Y.)

Market withdrawal: Extavia (EMA)

Regulatory2025-04-25EMA

A disease-specific convergence of host and Epstein-Barr virus genetics in multiple sclerosis.

Research2025-04-04Proceedings of the National Academy of Sciences of the United States of America

Role of innate immune cells in multiple sclerosis.

Research2025-02-17Frontiers in immunology

The Influence of SARS-CoV-2 Infection on the Development of Selected Neurological Diseases.

Research2024-08-09International journal of molecular sciences

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Major developments
Important regulatory approvalHigh impact
Cenrifki is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) without relapses in the last 2 years.2026-06-19
Clinical Milestones16View all 16
+8 more in the activity timeline below
Industry & Market3View
Regulatory Updates1View
  • 2026-06-19Approval — TolebrutinibCenrifki is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) without relapses in the last 2 years.
Activity timeline20

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Tolebrutinibapproved

Approval — Cenrifki is indicated for the treatment of adult patients with secondary progressive mult… (2026)

Approval — Riulvy is indicated for the treatment of adult and paediatric patients aged 13 years and… (2025)

Approval — Dimethyl fumarate Mylan is indicated for the treatment of adult and paediatric patients a… (2024)

Natalizumabapproved

Approval — Tyruko is indicated as single disease modifying therapy in adults with highly active rela… (2023)

Ublituximabapproved

Approval — Briumvi is indicated for the treatment of adult patients with relapsing forms of multiple… (2023)

Approval — Teriflunomide Accord is indicated for the treatment of adult patients and paediatric pati… (2022)

Research-associated treatments

Clinical trials

11 sponsors · 3 new · 4 completed in the last 12 months (net -1)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies
Recently completed

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2026emaApprovalTolebrutinib· Cenrifki is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) without relapses in the last 2 years. source ↗
2025emaApprovalTegomil fumarate· Riulvy is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS). source ↗
2024emaApprovalDimethyl fumarate· Dimethyl fumarate Mylan is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS). source ↗
2024emaApprovalDimethyl fumarate· Dimethyl fumarate Neuraxpharm is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS). source ↗
2024emaApprovalDimethyl fumarate· Dimethyl fumarate Accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS). source ↗
2023emaApprovalNatalizumab· Tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (RRMS) for the following patient groups: Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) (for exceptions and information about washout periods see sections 4.4 and 5.1) or Patients with rapidly evolving severe RRMS defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain Magnetic Resonance Imaging (MRI) or a significant increase in T2 lesion load as compared to a previous recent MRI. source ↗
2023emaApprovalUblituximab· Briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. source ↗
2022emaApprovalTeriflunomide· Teriflunomide Accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (MS) (please refer to section 5.1 for important information on the population for which efficacy has been established). source ↗
Safety updates
2025emaMarket withdrawalInterferon beta-1b· Extavia is indicated for the treatment of: patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis; patients with relapsing-remitting multiple sclerosis and two or more relapses within the last two years; patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses. source ↗
2023emaMarket withdrawalDimethyl fumarate· Dimethyl fumarate Neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis. source ↗
2023emaMarket withdrawalDimethyl fumarate· Dimethyl fumarate Accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS). source ↗
2023emaMarket withdrawalDimethyl fumarate· Dimethyl fumarate Polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis. source ↗
2023emaMarket withdrawalDimethyl fumarate· Dimethyl fumarate Mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis. source ↗
2023emaMarket withdrawalDimethyl fumarate· Dimethyl fumarate Teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS). source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

62 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20062025
Most influential

Axonal transection in the lesions of multiple sclerosis.

The New England journal of medicine · 1998 · 2,726 cites

Multiple sclerosis - a review.

European journal of neurology · 2019 · 1,306 cites

Multiple sclerosis: an immune or neurodegenerative disorder?

Annual review of neuroscience · 2008 · 1,237 cites
Recent publications

Neuroinflammation across neurological diseases.

Science (New York, N.Y.) · 2025 · 53 cites

A disease-specific convergence of host and Epstein-Barr virus genetics in multiple sclerosis.

Proceedings of the National Academy of Sciences of the United States of America · 2025 · 13 cites

Role of innate immune cells in multiple sclerosis.

Frontiers in immunology · 2025 · 8 cites

Estimated Brain Age in Healthy Aging and Across Multiple Neurological Disorders.

Journal of magnetic resonance imaging : JMRI · 2025 · 8 cites
Major themes8
  • Multiple Sclerosis40
  • Alzheimer Disease6
  • Gastrointestinal Microbiome6
  • Encephalomyelitis, Autoimmune, Experimental5
  • Brain4
  • Neurodegenerative Diseases4
  • Parkinson Disease4
  • Autoimmune Diseases3
Leading journals6
  • Frontiers in immunology4
  • International journal of molecular sciences4
  • Gut microbes3
  • Neurology3
  • Proceedings of the National Academy of Sciences of the United States of America3
  • Cells2
Leading researchers8
  • Barkhof F3
  • Baranzini SE2
  • Clarke JWE2
  • Cole JH2
  • Ding Y2
  • Kuhle J2
  • Levin MC2
  • Li H2
Affiliations (unnormalised)6
  • Center for Molecular Medicine2
  • College of Medicine2
  • College of Pharmacy2
  • Imperial College London2
  • Karolinska Institutet2
  • Lerner Research Institute2

Disease biology

5 matches

Key proteins & gene products studied in this disease. Number shows shared papers.

Related conditions

12 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Multiple sclerosis is an autoimmune disorder of the central nervous system that primarily affects young adults. It is characterized by sharply demarcated areas of demyelination in the white matter and by a clinical course that often involves recurrent attacks with partial recovery, although acute fulminating and chronic progressive forms also occur.

Causes

The underlying cause of multiple sclerosis is not fully defined in the supplied material. The literature grounding supports complex gene-environment interactions, with epidemiologic associations involving low vitamin D levels, smoking, childhood obesity, and Epstein-Barr virus infection.

Pathophysiology

Multiple sclerosis is an inflammatory demyelinating disease in which immune-mediated injury targets myelin in the central nervous system. The grounding also supports roles for cytokine and interleukin signaling, innate immunity, oxidative stress, signal transduction, and impaired remyelination, with some literature debating whether neurodegeneration contributes to irreversible disability.

Risk factors

The supplied literature identifies low serum vitamin D, smoking, childhood obesity, and Epstein-Barr virus infection as likely risk factors for disease development. Genetic susceptibility is also supported by the grounding through polymorphism and quantitative trait loci.

Current standard of care

The grounding supports disease-modifying treatment at the drug-class level, including immunomodulatory therapy such as glatiramer acetate. It also supports broader treatment approaches aimed at controlling inflammatory disease activity and addressing relapsing or progressive clinical courses, but does not provide enough detail to specify additional standard modalities beyond this.

AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.